People with schizophrenia are at higher risk than the general population of cardiometabolic diseases, the risk of which is further increased by some antipsychotics.

This analysis evaluated the long-term effects of lurasidone in patients with schizophrenia, who received lurasidone during a double-blind trial and its open-label extension study, or who received risperidone during the double-blind trial but then switched to lurasidone during the open-label study.

Lurasidone demonstrated sustained long-term efficacy and was associated with minimal changes in metabolic variables and prolactin levels.

Patients switching from risperidone to lurasidone experienced improvements in metabolic parameters and prolactin levels.

These findings confirm lurasidone’s long-term efficacy and favourable metabolic safety profile in patients with schizophrenia.